Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.
Cantor Global Healthcare Conference
Taming the Knowledge Sprawl: Strategies for Controlling Generative AIâ€™s Expanding Knowledge
Keynote Panel: The Continued Rise of AI: Embracing the Known and Unknown to Drive Business Results
Generative AI Solutions Showcase Session